New drug cocktail aims to wipe out esophageal tumors before surgery
NCT ID NCT07388095
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a combination of three drugs (adebrelimab, nimotuzumab, and chemotherapy) given before surgery to 22 patients with resectable esophageal squamous cell carcinoma. The main goal is to see if the cancer disappears completely after treatment. If it works, this approach could improve outcomes for patients with this type of cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adebrelimab, nimotuzumab, cisplatin, and albumin-bound paclitaxel
- What this could lead to
- If successful, this combination could become a new standard neoadjuvant therapy to improve complete tumor removal and survival in esophageal cancer.
- What could go wrong
- This is a small, early-phase exploratory trial with only 22 patients, so results may not be generalizable. The drug combination may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
- New drug duo aims to wipe out esophageal tumors before surgery
- Could a drug combo let some esophageal cancer patients skip surgery?
- New drug cocktail shows promise against tough esophageal cancer
- New triple therapy hopes to outsmart tough esophageal cancer
- New hope for esophageal cancer patients who failed immunotherapy